Neos Therapeutics (NEOS) Stock Price Down 7.7%

Shares of Neos Therapeutics Inc (NASDAQ:NEOS) traded down 7.7% during mid-day trading on Monday . The stock traded as low as $2.01 and last traded at $2.05. 509,073 shares were traded during trading, an increase of 37% from the average session volume of 371,612 shares. The stock had previously closed at $2.22.

Several equities research analysts recently weighed in on NEOS shares. Zacks Investment Research upgraded shares of Neos Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research report on Tuesday, April 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Neos Therapeutics in a research report on Wednesday, March 27th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Neos Therapeutics has a consensus rating of “Buy” and a consensus target price of $9.69.

The company has a debt-to-equity ratio of 5.51, a current ratio of 1.55 and a quick ratio of 1.37. The firm has a market capitalization of $105.39 million, a P/E ratio of -1.31 and a beta of 0.99.

Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Thursday, March 14th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. The firm had revenue of $15.39 million during the quarter, compared to analyst estimates of $18.90 million. Analysts expect that Neos Therapeutics Inc will post -0.66 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in the company. Deutsche Bank AG grew its holdings in Neos Therapeutics by 7.8% in the fourth quarter. Deutsche Bank AG now owns 61,269 shares of the company’s stock valued at $100,000 after purchasing an additional 4,414 shares during the last quarter. American International Group Inc. raised its holdings in shares of Neos Therapeutics by 63.9% in the 4th quarter. American International Group Inc. now owns 30,814 shares of the company’s stock worth $51,000 after purchasing an additional 12,016 shares during the period. Rhumbline Advisers grew its stake in shares of Neos Therapeutics by 52.4% in the fourth quarter. Rhumbline Advisers now owns 37,442 shares of the company’s stock valued at $62,000 after buying an additional 12,871 shares in the last quarter. Millennium Management LLC grew its stake in shares of Neos Therapeutics by 25.4% in the fourth quarter. Millennium Management LLC now owns 88,643 shares of the company’s stock valued at $146,000 after buying an additional 17,927 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new stake in Neos Therapeutics during the 4th quarter valued at approximately $35,000. 50.83% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Neos Therapeutics (NEOS) Stock Price Down 7.7%” was posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.themarketsdaily.com/2019/04/17/neos-therapeutics-neos-stock-price-down-7-7.html.

Neos Therapeutics Company Profile (NASDAQ:NEOS)

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

See Also: How to invest in a bear market

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.